Strategic partnerships and accelerating trial readouts position the company to replace revenue lost to patent cliffs.

By Pushkala Aripaka and Patrick Wingrove Oct 30 (Reuters) - AstraZeneca on Friday unveiled a restructuring programme aimed at ...

Oct 30 (Reuters) - AstraZeneca on Friday launched an unexpected restructuring drive aimed at investing in its new drug pipeline, hoping that annual savings of about $1.5 billion from the plan will ...

Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...

AstraZeneca (NYSE:AZN) reported continued revenue and earnings growth for the first nine months of 2026, supported by ...

Executive Vice President, BioPharmaceuticals Business Unit - Ruud Dobber ...

The company's cancer drug portfolio was its fastest-growing business in the quarter, with sales rising 17%. Tagrisso, ...

AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.

AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to ...

Aradhana Sarin, AstraZeneca CFO, joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's ...

AstraZeneca has punted a pair of early-phase prostate cancer progra | AstraZeneca has punted a pair of early-phase prostate ...

AstraZeneca stock jumps 7% to $186.65 as nine-month revenue rises 7%, core EPS gains 14%, and new medicine approvals ...